Last Updated: November 16, 2026

EXEMESTANE Drug Patent Profile

« Back to Dashboard


DrugPatentWatch® Litigation and Generic Entry Outlook for Exemestane

A generic version of EXEMESTANE was approved as exemestane by RISING on March 10th, 2017.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for EXEMESTANE?
  • What are the global sales for EXEMESTANE?
  • What is Average Wholesale Price for EXEMESTANE?
Summary for EXEMESTANE
Recent Clinical Trials for EXEMESTANE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Anhui Provincial Cancer HospitalPHASE2
Eli Lilly and CompanyPHASE3
Herbert Irving Comprehensive Cancer CenterPHASE2

See all EXEMESTANE clinical trials

Pharmacology for EXEMESTANE
Drug ClassAromatase Inhibitor
Mechanism of ActionAromatase Inhibitors

US Patents and Regulatory Information for EXEMESTANE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Amneal Pharms EXEMESTANE exemestane TABLET;ORAL 206421-001 Dec 28, 2018 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Hikma EXEMESTANE exemestane TABLET;ORAL 077431-001 Apr 1, 2011 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Dr Reddys Labs Sa EXEMESTANE exemestane TABLET;ORAL 208764-001 Aug 8, 2019 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Qilu EXEMESTANE exemestane TABLET;ORAL 213547-001 Apr 13, 2020 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Breckenridge EXEMESTANE exemestane TABLET;ORAL 211031-001 Feb 21, 2019 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Exemestane Market Dynamics, Patent Status, Generic Competition, and Financial Trajectory

Last updated: November 9, 2026

Exemestane is a mature, off-patent oral aromatase inhibitor marketed originally as Aromasin by Pharmacia and later Pfizer. The U.S. product was approved in 1999 for postmenopausal women with estrogen-receptor-positive breast cancer. Its commercial trajectory followed the standard lifecycle for an oncology small molecule: premium branded sales during the exclusivity period, loss of protection after core patent expiry, and subsequent conversion to a low-cost generic market.

The product remains clinically relevant, but its financial profile is no longer driven by originator pricing. Current value is concentrated in generic volume, hospital and retail reimbursement, international markets, and supply reliability rather than patent exclusivity.

What is exemestane and how is it used?

Exemestane is an irreversible steroidal aromatase inhibitor. It suppresses estrogen production by binding irreversibly to aromatase, the enzyme that converts androgens into estrogens.

The FDA-approved U.S. indications include:

  • Adjuvant treatment of postmenopausal women with estrogen-receptor-positive early breast cancer after two to three years of tamoxifen.
  • Treatment of advanced breast cancer in postmenopausal women whose disease has progressed after tamoxifen therapy. (FDA, 2011)

The standard tablet strength is 25 mg. The product is administered orally, generally once daily after a meal. The reference product was Aromasin, originally developed by Pharmacia and later commercialized within Pfizer’s portfolio.

Exemestane competes primarily with:

  • Anastrozole, marketed originally as Arimidex.
  • Letrozole, marketed originally as Femara.
  • Tamoxifen, a selective estrogen-receptor modulator.
  • Fulvestrant, an injectable estrogen-receptor degrader used mainly in advanced disease.

What is the FDA regulatory status of exemestane?

The FDA approved Aromasin in December 1999 under a New Drug Application for postmenopausal breast cancer. The drug is a conventional small molecule, not a biologic, so it is subject to abbreviated new drug application, or ANDA, competition rather than biosimilar regulation.

Regulatory milestone Date or status
U.S. approval of Aromasin December 1999
Active ingredient Exemestane
Dosage form Oral tablet
Reference product Aromasin
Regulatory pathway for competitors ANDA
Current regulatory category Generic small molecule
Biosimilar pathway applicable? No

The FDA-approved generic market includes exemestane tablets supplied by multiple manufacturers. Availability can vary by strength, bottle size, wholesaler inventory, and manufacturing site. FDA labeling identifies exemestane as therapeutically interchangeable through approved generic products when the relevant ANDA has an AB rating in the Orange Book. (FDA, 2024a)

What patents protect exemestane?

The principal historic U.S. compound patent associated with exemestane is U.S. Patent No. 4,808,616, covering 6-methylene steroid compounds, including exemestane-related subject matter. The patent was assigned to the Pharmacia-related organization and issued in 1989.

Patent Subject matter Historic status
U.S. Patent No. 4,808,616 Exemestane-related steroid compounds and pharmaceutical applications Expired
Core active-ingredient protection Exemestane compound Expired
Current Orange Book blocking protection No active core patent identified No current protection

The patent’s ordinary pre-URAA term was calculated from its 1989 grant date, producing an expiration date in 2006. Any regulatory patent-term adjustment or extension would not preserve a current blocking right in the U.S. market. The core patent estate is therefore commercially exhausted.

The remaining intellectual-property issues are narrower. They can include formulation claims, manufacturing processes, polymorphs, salt or crystal forms, and method-of-use claims in particular jurisdictions. Those rights generally do not recreate the broad exclusivity once provided by the compound patent.

When did exemestane lose exclusivity?

Exemestane lost its principal commercial protection in the mid-2000s, after the compound patent expired and the five-year new chemical entity exclusivity period from the 1999 FDA approval ended.

Exclusivity category Approximate U.S. timing
FDA approval 1999
Five-year NCE exclusivity Through approximately 2004
Core compound patent Expired in the 2000s
Generic competition Emerged after patent and regulatory barriers cleared
Current exclusivity None of commercial significance

The precise generic launch date differed by manufacturer and market. Generic availability expanded after ANDA approvals, procurement qualification, and commercial supply arrangements were completed. The gap between legal patent expiry and broad pharmacy availability reflects manufacturing, regulatory, and distribution timing rather than continuing patent exclusivity.

What is the Orange Book status of exemestane?

Exemestane is an established generic product in the FDA Orange Book. The relevant market structure is no longer based on a protected branded reference product with active listed patents.

The Orange Book remains important for:

  • Confirming approved reference and generic products.
  • Reviewing therapeutic-equivalence ratings.
  • Identifying any currently listed patents.
  • Tracking approved dosage forms and manufacturers.
  • Evaluating the legal basis for ANDA approval.

For a mature product such as exemestane, Orange Book analysis should distinguish between historical patents and patents that remain enforceable against a new ANDA. The presence of an old patent number in historical records does not create current market exclusivity.

How many patents cover exemestane today?

No active U.S. patent estate appears to provide broad exclusivity over the exemestane molecule. Historical patents covered the active ingredient and its original pharmaceutical use, but those rights have expired.

The practical patent landscape has three layers:

  1. Core molecule patents, which are expired.
  2. Formulation and manufacturing patents, which may have existed in limited jurisdictions or for limited periods.
  3. Method-of-use patents, which may cover specific treatment sequencing, patient populations, or dosing strategies.

The third category has limited commercial impact because physicians can often prescribe generic exemestane for unpatented indications, and ANDA litigation depends on the precise claims listed against the reference product.

What formulations are protected by exemestane patents?

Aromasin was supplied as a 25 mg oral tablet. Formulation protection was commercially less important than compound protection because the dosage form is a conventional immediate-release tablet.

Potential formulation claim categories include:

  • Tablet composition.
  • Excipients and coating.
  • Stability and storage.
  • Particle size or crystalline form.
  • Manufacturing process.
  • Food-effect or bioavailability characteristics.

Generic manufacturers generally avoid infringement exposure by using independently developed excipient systems and manufacturing processes, provided their products meet FDA bioequivalence and quality requirements. No formulation patent is widely recognized as a current U.S. barrier to ordinary exemestane tablets.

Are there Paragraph IV challenges for exemestane?

Paragraph IV litigation was relevant during the transition from Aromasin to generic exemestane. An ANDA applicant may file a Paragraph IV certification when it asserts that a listed patent is invalid, unenforceable, or not infringed.

For current commercial planning, Paragraph IV risk is low because:

  • The core U.S. patent rights are expired.
  • Generic products are already approved and marketed.
  • No active broad patent appears to prevent ordinary generic entry.
  • Any remaining dispute would likely concern a narrow formulation, process, or method claim.

Publicly significant current Paragraph IV litigation does not appear to define the U.S. exemestane market. Any historical litigation should be separated from current entry risk. A settled case involving an early generic applicant would not, by itself, indicate a continuing barrier after the relevant patents expired.

What patent litigation affects exemestane?

The principal legal risk has shifted from originator patent enforcement to ordinary generic-market disputes, including:

  • ANDA certification disputes.
  • Trade-secret or manufacturing-process claims.
  • Product liability and labeling litigation.
  • Contract disputes involving supply and distribution.
  • International patent claims relating to specific formulations.

The absence of an active broad patent estate reduces the likelihood of a market-wide injunction. Litigation could still affect an individual supplier if it involves a process patent, regulatory exclusivity issue, quality failure, or supply agreement. No widely reported current U.S. litigation appears to threaten the generic market as a whole.

Which companies are challenging or supplying exemestane?

Exemestane is supplied by a broad generic manufacturer base. Depending on market and time period, suppliers have included large multinational generic companies, specialty pharmaceutical manufacturers, and contract manufacturers.

The competitive field typically includes:

  • Teva Pharmaceuticals.
  • Sandoz.
  • Mylan, now part of Viatris.
  • Sun Pharmaceutical Industries.
  • Dr. Reddy’s Laboratories.
  • Cipla.
  • Accord Healthcare.
  • Other regional ANDA and international suppliers.

Supplier participation changes as contracts, manufacturing economics, and shortages change. The commercial market is more fragmented than the branded market was under Pfizer.

How does exemestane compare with anastrozole and letrozole?

Exemestane competes in a class where all three principal oral aromatase inhibitors are available as generics.

Product Type Original brand Current market position
Exemestane Steroidal, irreversible aromatase inhibitor Aromasin Generic
Anastrozole Nonsteroidal aromatase inhibitor Arimidex Generic
Letrozole Nonsteroidal aromatase inhibitor Femara Generic

Clinical selection can depend on prior tamoxifen exposure, tolerability, bone-health considerations, recurrence-risk strategy, physician preference, formulary status, and patient adherence. Because all three products face generic competition, pricing and supply reliability often matter more to payers than brand differentiation.

Exemestane retains a specific clinical position as a steroidal irreversible inhibitor and is frequently used after tamoxifen. That positioning supports continued demand despite the absence of patent protection.

What is the financial trajectory for exemestane?

The financial trajectory has four stages.

Branded growth period

From the 1999 approval through the protected-market period, Aromasin generated branded oncology revenue for Pharmacia and later Pfizer. Revenue was supported by clinical adoption, post-tamoxifen use, and breast-cancer treatment guidelines.

Mature branded period

Before generic erosion, Aromasin faced direct competition from Arimidex and Femara. The class was already competitive, which limited the pricing power of any single aromatase inhibitor.

Generic conversion

After loss of compound protection, the market shifted from one principal branded supplier to multiple generic manufacturers. Net prices fell, pharmacy substitution increased, and Pfizer’s product lost most of its economic value.

Current commodity phase

Current market economics are driven by:

  • Prescription volume.
  • Generic reimbursement rates.
  • Pharmacy benefit manager contracts.
  • Manufacturing cost.
  • Active pharmaceutical ingredient supply.
  • Wholesaler inventory.
  • Periodic shortages or supplier exits.

Pfizer does not generally report current exemestane revenue as a material standalone product line in its public financial reporting. That limits the ability to calculate a current originator revenue figure from company filings. The commercially relevant revenue pool is now distributed among generic suppliers and is not usually disclosed by molecule.

What generic entry risks exist?

Generic entry risk for a new supplier is legally low but commercially meaningful.

Risk category Assessment
Broad patent blocking Low
FDA approval risk Moderate, depending on quality and bioequivalence
Manufacturing risk Moderate
Pricing pressure High
Supplier concentration risk Moderate
Shortage risk Possible if manufacturers exit
Biosimilar risk Not applicable
Originator litigation risk Low

A new entrant would face price compression rather than patent exclusion. The principal barriers are FDA-compliant manufacturing, reliable API sourcing, pharmacokinetic equivalence, supply contracts, and adequate scale.

What licensing deals affect exemestane?

Exemestane originated within Pharmacia’s pharmaceutical operations, which later became part of Pfizer through corporate acquisitions. The principal commercial transaction was therefore corporate portfolio consolidation rather than a currently important independent license.

No major current licensing arrangement appears to control U.S. generic exemestane access. International licensing, contract manufacturing, and distribution agreements can affect individual suppliers but do not establish market-wide exclusivity.

Does exemestane face biosimilar competition?

No. Exemestane is a chemically synthesized small molecule, not a biologic. Competitors enter through ANDAs as generics rather than through the abbreviated biosimilar pathway.

This distinction matters commercially. Generic applicants generally rely on pharmaceutical equivalence and bioequivalence, while biosimilar applicants must demonstrate biosimilarity to a biologic reference product. Exemestane therefore has no biosimilar development risk.

What is the geographic coverage of exemestane patents?

The original Pharmacia patent family had international counterparts, but the commercial significance of those rights has largely expired in major markets. Current exposure depends on local patent terms, regulatory exclusivities, national reimbursement rules, and generic approval status.

The U.S., European Union, Canada, Japan, and major emerging markets generally treat exemestane as a mature generic medicine. Country-level differences remain in:

  • Approval timing.
  • Reference-product requirements.
  • Patent linkage.
  • Reimbursement.
  • Tender participation.
  • Local manufacturing rules.
  • Import and API controls.

A global launch plan therefore requires country-by-country regulatory and patent review even though broad molecule-level exclusivity has ended.

How strong is the exemestane patent estate?

The current patent estate is weak as a barrier to ordinary generic tablets. The core compound protection is expired, the branded product has lost exclusivity, and multiple generic suppliers operate in the market.

Factor Current assessment
Molecule patent strength Exhausted
Formulation protection Limited or non-blocking
Method-of-use protection Narrow commercial relevance
Orange Book leverage Low
Generic substitution risk High
Originator revenue protection Low
Manufacturing differentiation Potentially meaningful

The remaining competitive advantage is operational rather than legal. Manufacturers with reliable supply, low-cost production, global registrations, and strong payer access are better positioned than companies relying on patent protection.

Key Takeaways

  • Exemestane is the active ingredient in Aromasin, approved by the FDA in 1999.
  • The product is a steroidal irreversible aromatase inhibitor used mainly in postmenopausal breast cancer.
  • The principal historic U.S. compound patent, U.S. Patent No. 4,808,616, is expired.
  • Exemestane has no meaningful current molecule-level exclusivity in the U.S.
  • Competition occurs through ANDA-approved generics, not biosimilars.
  • Generic pricing, supply reliability, API sourcing, and reimbursement determine current market economics.
  • Pfizer no longer reports material standalone exemestane revenue in public financial disclosures.
  • Patent litigation and Paragraph IV risk are low for ordinary generic tablets, although narrow manufacturing or formulation disputes remain possible.
  • The commercial market is mature, fragmented, and exposed to substantial price pressure.

FAQs About Exemestane Market and Patent Risk

Is exemestane still under patent?

No broad U.S. patent currently protects the exemestane molecule. The principal historic compound patent has expired.

Is Aromasin still sold as a branded drug?

Aromasin may remain available in some markets, but branded commercial importance has declined sharply because generic exemestane tablets are available.

Can a company launch a generic version of exemestane without a license from Pfizer?

In the United States, a company generally does not need a Pfizer license to market an approved generic after applicable patents and exclusivities expire. It must obtain FDA approval and satisfy manufacturing and bioequivalence requirements.

Why can exemestane prices rise despite expired patents?

Prices can rise temporarily because of manufacturer shortages, API constraints, wholesaler disruptions, contract changes, or supplier exits. Patent protection is not required for short-term generic price volatility.

Is exemestane more commercially durable than letrozole or anastrozole?

All three products are mature generics. Exemestane has a differentiated steroidal mechanism and a recognized post-tamoxifen role, but its commercial durability depends primarily on clinical utilization and supply economics rather than exclusivity.

References

  1. Food and Drug Administration. (1999). Aromasin (exemestane) approval letter and regulatory review. U.S. Department of Health and Human Services.

  2. Food and Drug Administration. (2011). Aromasin prescribing information. U.S. Department of Health and Human Services.

  3. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

  4. Food and Drug Administration. (2024b). Drugs@FDA: FDA-approved drugs database. U.S. Department of Health and Human Services.

  5. U.S. Patent and Trademark Office. (1989). U.S. Patent No. 4,808,616: 6-Methylene steroids, process for their preparation and pharmaceutical compositions containing them. U.S. Department of Commerce.

  6. Pfizer Inc. (Various years). Annual report and Form 10-K filings. Pfizer Inc.

  7. National Cancer Institute. (2024). Exemestane. National Institutes of Health.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.